Psoriatic Arthritis News Archive

Higher Cardiovascular Risk Seen With Psoriatic Arthritis

Higher Cardiovascular Risk Seen With Psoriatic Arthritis

Cardiovascular risk should be carefully evaluated in patients with psoriatic arthritis.

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

Researchers compared definitions of remission and low disease activity in patients with psoriatic arthritis.

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

Investigators examined the performance of various definitions in patients with PsA and psoriasis.

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.

Radiographic Changes in PsA: Conventional Synthetic DMARDs vs Anti-TNF Therapy

Radiographic Changes in PsA: Conventional Synthetic DMARDs vs Anti-TNF Therapy

Investigators assessed radiographic progression in patients with psoriatic arthritis following transition from conventional synthetic disease-modifying rheumatic drugs to anti-tumor necrosis factor-α therapy.

Use of DAPSA28 for Assessment of Disease Activity in Psoriatic Arthritis

Use of DAPSA28 for Assessment of Disease Activity in Psoriatic Arthritis

Investigators sought to determine the validity of using a simplified scoring tool that assesses 28 joint counts compared with the original 66/68 joint counts in patients with psoriatic arthritis.

PsA Activity During and After Pregnancy Affected by Biologic Therapy

PsA Activity During and After Pregnancy Affected by Biologic Therapy

Investigators explore the impact of pregnancy on PsA disease activity, as well as the effect of biologic therapy on PsA disease activity during and following pregnancy.

Risk for Type 2 Diabetes, Cardiovascular Disease Elevated in Patients With Psoriatic Arthritis

Risk for Type 2 Diabetes, Cardiovascular Disease Elevated in Patients With Psoriatic Arthritis

Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.

Sustained Improvements in PsA With Certolizumab Pegol Monotherapy, DMARD Combination

Sustained Improvements in PsA With Certolizumab Pegol Monotherapy, DMARD Combination

Results from the RAPID-PsA study showed that patients with PsA who are treated with certolizumab pegol sustained improvements over the course of 4 years when it is taken as a monotherapy or concomitant with DMARDs.

Incidence, Predictors of Orthopedic Surgery in Psoriatic Arthritis

Incidence, Predictors of Orthopedic Surgery in Psoriatic Arthritis

Researchers quantified the incidence of orthopedic procedures in patients with psoriatic arthritis.

Effects of Age, Disease Duration on Bone Erosions in Psoriasis, Psoriatic Arthritis

Effects of Age, Disease Duration on Bone Erosions in Psoriasis, Psoriatic Arthritis

Data show that psoriatic arthritis acts as a strong enhancer of age-related catabolic bone damage.

Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis

Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis

Rheumatologist-assessed inflammatory back pain (IBP) or the criteria for IBP developed for ankylosing spondylitis might not perform well when determining axial involvement in psoriatic arthritis.

Assessing Disease Activity During, After Pregnancy in Psoriatic Arthritis

Assessing Disease Activity During, After Pregnancy in Psoriatic Arthritis

Disease activity was altogether low and stable from preconception to 1 year postpartum among pregnant women with psoriatic arthritis.

Ixekizumab Demonstrates No New Safety Concerns for Treatment of Psoriatic Arthritis

Ixekizumab Demonstrates No New Safety Concerns for Treatment of Psoriatic Arthritis

The safety profile of ixekizumab in the treatment of psoriatic arthritis is similar to the safety profile observed with ixekizumab for the treatment of plaque psoriasis.

Sustained Minimal Disease Activity in Psoriatic Arthritis Prevents Progression of Atherosclerosis

Sustained Minimal Disease Activity in Psoriatic Arthritis Prevents Progression of Atherosclerosis

Sustained minimal disease activity should be maintained for a prolonged period in order to prevent progression of carotid atherosclerosis and arterial stiffness in patients with PsA.

OMERACT Group Develops Reliable Ultrasound Definition of Enthesitis in PsA, SpA

OMERACT Group Develops Reliable Ultrasound Definition of Enthesitis in PsA, SpA

A final reliable ultrasound score and definition of enthesitis in SpA and PsA were produced by the OMERACT group.

Reduced Synovial Inflammation With Secukinumab in Psoriatic Arthritis

Reduced Synovial Inflammation With Secukinumab in Psoriatic Arthritis

Treatment with secukinumab over 24 weeks led to a decrease of synovial inflammation and no progression of catabolic and anabolic bone changes in patients with PsA.

Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks

Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks

ABT-122 demonstrated acceptable tolerability and maintenance of efficacy at 36 weeks in patients with RA or PsA receiving background methotrexate.

Minimal Disease Activity Provides Valid Assessment of Adalimumab-Treated Psoriatic Arthritis

Minimal Disease Activity Provides Valid Assessment of Adalimumab-Treated Psoriatic Arthritis

Minimal disease activity provided a stable and valid assessment of clinical status over the course of 24 months in patients with psoriatic arthritis.

Few Sonographic Enthesitis Scoring Instruments Validated in Psoriatic Arthritis

Few Sonographic Enthesitis Scoring Instruments Validated in Psoriatic Arthritis

Sonographic enthesitis scoring instruments have been developed for spondyloarthritis, but only a few have been validated in psoriatic arthritis.

Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis

Prevalence of Psoriatic Arthritis Quantified in Patients With Psoriasis

Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.

Widespread Pain Common, Linked to Worse Patient-Reported Disease Activity in PsA

Widespread Pain Common, Linked to Worse Patient-Reported Disease Activity in PsA

Widespread nonarthritic pain is linked to worse patient-reported and composite psoriatic arthritis activity measures.

Axial Involvement in Psoriatic Arthritis Associated With Poorer Clinical Outcomes, Quality of Life

Axial Involvement in Psoriatic Arthritis Associated With Poorer Clinical Outcomes, Quality of Life

Researchers analyzed the characteristics of patients with psoriatic arthritis with and without axial involvement.

Examining the Influence of Disease Manifestations on Quality of Life in Psoriatic Arthritis

Examining the Influence of Disease Manifestations on Quality of Life in Psoriatic Arthritis

Health-related quality of life was diminished in psoriatic arthritis at time of diagnosis compared with the general population.

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

Physician's Global Assessment Reliable for Evaluating Disease Activity in Psoriatic Arthritis

Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

High-Intensity Interval Training Has No Effect on Disease Activity in Psoriatic Arthritis

High-intensity interval training showed no clear effects on disease activity markers in patients with psoriatic arthritis.

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

Similar Quality of Life Reported in Rheumatoid Arthritis, Psoriatic Arthritis

Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.

TNFi More Effective in Men vs Women With Psoriatic Arthritis

TNFi More Effective in Men vs Women With Psoriatic Arthritis

Male gender was associated with better biologic treatment effectiveness in psoriatic arthritis.

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.

Low Conversion Rate of Quantiferon-TB Test in TNF Inhibitor-Treated Patients

Low Conversion Rate of Quantiferon-TB Test in TNF Inhibitor-Treated Patients

Investigators sought to determine the rate of conversion of Quantiferon-TB Gold screening test in patients taking anti-TNF therapy.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

Initial response to psoriatic arthritis therapy has a predictive value of long-term outcomes as early as 3 months after treatment initiation.

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

Results from the FUTURE 2 study show that patients with PsA who were treated with secukinumab achieved early and sustained minimal disease activity over 2 years of therapy.

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

A cohort study was conducted to determine the long-term outcomes especially of cardiovascular and kidney diseases in patients with psoriatic arthritis with comorbid hyperuricemia.

Risk of Liver Disease Increased With Psoriatic Arthritis

Risk of Liver Disease Increased With Psoriatic Arthritis

There is a higher risk for liver disease in patients with inflammatory disorders.

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

The FDA has approved tofacitinib and tofacitinib extended release to treat active psoriatic arthritis.

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

Investigators compared composite scores defining low disease activity state or remission in an existing real-life data set of patients with PsA.

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

Disease severity and activity in psoriatic arthritis may predict coronary plaque burden better than traditional risk factors.

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

Cardiovascular risk assessment tools in patients with PsA have been shown to underestimate the risk for carotid subclinical atherosclerosis.

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

The FDA has approved ixekizumab for the treatment of adults with psoriatic arthritis.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.

Tofacitinib May Reduce Disease Activity in Active Psoriatic Arthritis

Tofacitinib May Reduce Disease Activity in Active Psoriatic Arthritis

Tofacitinib may be effective in reducing psoriatic arthritis activity in patients with inadequate response to TNF inhibitors.

Current Status of Targeting Remission in Patients With Psoriatic Arthritis

Current Status of Targeting Remission in Patients With Psoriatic Arthritis

Although remission is the ultimate goal among patients with psoriatic arthritis and their physicians, many unanswered questions on what precisely we should aim to achieve still remain.

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

FDA Approves Simponi Aria For Active Ankylosing Spondylitis, Psoriatic Arthritis

Simponi Aria has been approved by the FDA for treating PsA or ankylosing spondylitis.

Safety and Efficacy of Intravenous Golimumab in Psoriatic Arthritis

Safety and Efficacy of Intravenous Golimumab in Psoriatic Arthritis

Psoriatic arthritis treatment with intravenous golimumab leads to improved outcomes.

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

Inhibitors of interkeukins 6, 12, 23 and 17A were shown to be effective and generally well-tolerated agents for the treatment of psoriatic arthritis.

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.

Real-World Data Validates Minimal Disease Activity Index in PsA

Real-World Data Validates Minimal Disease Activity Index in PsA

Overall improvements in rates of minimal disease activity are achieved in patients with PsA when they are treated with anti-tumor necrosis factor agents

Positive Correlation Between Smoking Amount, Duration and Psoriasis

Positive Correlation Between Smoking Amount, Duration and Psoriasis

Smoking is associated with the risk of psoriasis.

Noninvasive Test Monitors Hepatic Fibrosis in Psoriasis Patients Taking Methotrexate

Noninvasive Test Monitors Hepatic Fibrosis in Psoriasis Patients Taking Methotrexate

A noninvasive test can be used to help monitor for risk of worsening fibrosis in psoriasis patients who have elevated hepatic steatosis.

Sonographic Enthesitis as a Potential Marker of Radiographic Damage Severity in PsA

Sonographic Enthesitis as a Potential Marker of Radiographic Damage Severity in PsA

The association between sonographic enthesitis and severity of radiographic features of peripheral and axial joint damage in psoriatic arthritis was examined in a cross-sectional study.

Findings of Psoriatic Arthritis Treatment Trends

Findings of Psoriatic Arthritis Treatment Trends

Less than 40% of psoriatic arthritis patients were treated with a bDMARD.

Dalazatide Effective Treatment for Skin Lesions in Plaque Psoriasis

Dalazatide Effective Treatment for Skin Lesions in Plaque Psoriasis

Dalazatide treatment can improve skin lesions for patients with plaque psoriasis.

First Interchangeability Study Started for Adalimumab Biosimilar

First Interchangeability Study Started for Adalimumab Biosimilar

The first US study to examine an interchangeability designation for an adalimumab biosimilar candidate is investigating interchangeability between BI 695501 and Humira 40mg/0.8mL.

Ultrasound-Detected Synovitis Predicts Short-term PsA Disease Flare

Ultrasound-Detected Synovitis Predicts Short-term PsA Disease Flare

The ability of Power Doppler Ultrasound to predict short-term psoriatic arthritis disease flare was investigated in a new study.

Adalimumab Biosimilar ABP 501 Safe, Effective for Psoriasis

Adalimumab Biosimilar ABP 501 Safe, Effective for Psoriasis

ABP 501 is safe to use for treating moderate to severe plaque psoriasis.

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

The researchers noted that the small changes in lipid profile do not account for the cardiovascular benefits seen in patients taking etanercept.

Psoriasis Patients Have Higher Cardiometabolic Comorbidity Rates

Psoriasis Patients Have Higher Cardiometabolic Comorbidity Rates

Psoriasis patients have high rates hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.

Tofacitinib Found to Improve Nail Psoriasis

Tofacitinib Found to Improve Nail Psoriasis

There was improvement in nail psoriasis severity at 16 weeks compared with placebo that was maintained through 52 weeks.

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

Repeated serum amyloid A measurements could act as an additional marker for monitoring disease activity over time in patients with psoriatic arthritis.

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.

Uveitis Risk Higher Among Patients With Psoriasis

Uveitis Risk Higher Among Patients With Psoriasis

Patients with severe psoriasis and those with mild psoriasis and concomitant psoriatic arthritis have an increased risk of uveitis.

First Line Biologic for Psoriasis Influenced By Certain Factors

First Line Biologic for Psoriasis Influenced By Certain Factors

Psoriatic arthritis, patient weight, registration country and more influence first-line biologic treatment selection for patients with psoriasis.

Women Have Lower Psoriasis Area and Severity Index Scores Than Men

Women Have Lower Psoriasis Area and Severity Index Scores Than Men

Women were found to have a lower median of scores in the Psoriasis Area and Severity Index than men.

Psoriatic Arthritis Development Predicted by Musculoskeletal Symptoms

Psoriatic Arthritis Development Predicted by Musculoskeletal Symptoms

Prospective cohort study of patients with psoriasis who were assessed annually to examine for development of clinical psoriatic arthritis.

Secukinumab Efficacy for Psoriasis Examined After Treatment Pause

Secukinumab Efficacy for Psoriasis Examined After Treatment Pause

Findings come from 2 trials; one compared secukinumab with placebo, whereas the other compared secukinumab with placebo and etanercept.

Depression Significantly Increases Psoriatic Arthritis Risk Among Patients With Psoriasis

Depression Significantly Increases Psoriatic Arthritis Risk Among Patients With Psoriasis

Study evaluated clinical data to determine a possible role of major depressive disorders in the progression of inflammatory disease.

Psoriasis Treatment Negatively Impacted By Interrupted Ixekizumab Therapy

Psoriasis Treatment Negatively Impacted By Interrupted Ixekizumab Therapy

Most patients with psoriasis who were withdrawn from ixekizumab therapy experienced disease relapse.

Psoriatic Arthritis Strongly Linked With Developing Diabetes Mellitus

Psoriatic Arthritis Strongly Linked With Developing Diabetes Mellitus

Researchers find that higher levels of disease activity predict the development of diabetes mellitus in patients with psoriatic arthritis.

Childhood Psoriasis Also Impacts Parents' Quality of Life

Childhood Psoriasis Also Impacts Parents' Quality of Life

Emotional well-being negatively impacted among parents with affected children.

Psoriasis Symptoms Reduced With Long-Term Weight Loss

Psoriasis Symptoms Reduced With Long-Term Weight Loss

Obese patients with psoriasis experience quality-of-life improvement after losing significant amounts of weight.

Psoriasis Among Skin Diseases With Largest Impact on Well-Being

Psoriasis Among Skin Diseases With Largest Impact on Well-Being

Highest risk for reduction in HRQoL for hidradenitis suppurativa, blistering conditions, psoriasis

Perceived Stigmatization Common for Those With Psoriasis

Perceived Stigmatization Common for Those With Psoriasis

Researchers found that lower education, higher disease visibility, severity, duration, and Type D personality were tied to stigmatization.

New Clinical Trial Results: Safety and Efficacy of Tofacitinib in PsA

New Clinical Trial Results: Safety and Efficacy of Tofacitinib in PsA

Results were announced from a phase 3 trials assessing safety and efficacy of tofacitinib citrate for active psoriatic arthritis

Lack of Dose Response Found for Experimental IL-6 Inhibitor in PsA

Lack of Dose Response Found for Experimental IL-6 Inhibitor in PsA

Data from a Phase 2b clinical trial supported the safety and efficacy of clazakizumab in active psoriatic arthritis with or without methotrexate.

Preop PsA Not an Independent Predictor of Postop Pain or Function After THA

Preop PsA Not an Independent Predictor of Postop Pain or Function After THA

In this nested case-control study, after controlling for age, sex, diagnosis, ASA class, race, preoperative WOMAC pain and function scores, and smoking history, neither PsA and PsC were found to be risk factors for worse THA outcomes.

Golimumab Improves Long-Term Radiographic Outcomes in Psoriatic Arthritis

Golimumab Improves Long-Term Radiographic Outcomes in Psoriatic Arthritis

Results from the GO-REVEAL trial indicate that golimumab treatment is associated with long-term improvement in psoriatic arthritis.

Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune Disorders

Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune Disorders

Normal skin tissue morphology restored in psoriatic mice implanted with microencapsulated cytokine converter transgenic designer cells.

Outcomes From TICORA Trial for Psoriatic Arthritis

Outcomes From TICORA Trial for Psoriatic Arthritis

A targeted treatment approach may provide benefit for patients with psoriatic arthritis.

Psoriatic Arthritis More Effectively Treated Through Treat-To-Target Approach

Psoriatic Arthritis More Effectively Treated Through Treat-To-Target Approach

Both early intervention and targeted treatment more effectively treat psoriatic arthritis than standard care, according to data published in The Lancet.

Immunologic Advances Reveal New Targets in Psoriasis and Psoriatic Arthritis

Immunologic Advances Reveal New Targets in Psoriasis and Psoriatic Arthritis

Recent research has identified new targeted therapies for psoriasis and psoriatic arthritis.

Sign Up for Free e-newsletters